Occupational cannabis exposure and allergy risks.


Journal

Occupational and environmental medicine
ISSN: 1470-7926
Titre abrégé: Occup Environ Med
Pays: England
ID NLM: 9422759

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 06 2018
revised: 29 10 2018
accepted: 06 11 2018
pubmed: 17 12 2018
medline: 13 11 2019
entrez: 17 12 2018
Statut: ppublish

Résumé

Cannabis allergy has mainly been described following recreational use but some cases also point to cannabis sensitisation as a result of occupational exposure. As a consequence, little is known on the prevalence and clinical phenotype of occupational cannabis allergy. Therefore, this study aims to explore the allergy-associated health risks of occupational cannabis exposure in Belgian police force personnel. 81 participants, active in the police force, reporting regular occupational cannabis exposure during the past 12 months, were included. History was combined with a standardised questionnaire on allergies and cannabis exposure.Basophil activation tests (BATs) with a crude cannabis extract and rCan s 3 were performed. In addition, specific (s)IgE rCan s 3 as well as sIgE to house dust mite, six pollen and three mould allergens were quantified. Although 42% of the participants reported respiratory and/or cutaneous symptoms on occupational cannabis exposure, all cannabis diagnostics were entirely negative, except one symptomatic case demonstrating a borderline result. Furthermore, there is no significant difference between the groups with and without symptoms on cannabis exposure in terms of allergenic sensitisations. The origins of the reported respiratory and cutaneous symptoms during cannabis exposure remain elusive but are probably due to non-immune reactions. It should be noted that the study was volunteer-based possibly reflecting an excessive number of symptomatic individuals. Nevertheless, as only one participant reported using fully protective gear, much improvement is needed for reducing the number of symptoms reported on duty, independent of their origin.

Identifiants

pubmed: 30554157
pii: oemed-2018-105302
doi: 10.1136/oemed-2018-105302
doi:

Substances chimiques

Allergens 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

78-82

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ine Ilona Decuyper (II)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Athina Van Gasse (A)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Margaretha Antje Faber (MA)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Christel Mertens (C)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Jessy Elst (J)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Hans-Peter Rihs (HP)

Institute for Prevention and Occupational Medicine, German Social Accident Insurance, Ruhr-University Bochum, Bochum, Germany.

Vito Sabato (V)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Hilde Lapeere (H)

Ghent University Hospital, University of Ghent, Gent, Belgium.

Margo Hagendorens (M)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Chris Bridts (C)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Luc De Clerck (L)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Didier Ebo (D)

Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH